Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative medications operate by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to consumption. By triggering GLP-1 receptors in the pancreas, these substances boost insulin secretion and

The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight decrease – they exhibit intriguing differences